---
title: "Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285935233.md"
description: "Guggenheim analyst Seamus Fernandez has reiterated a Buy rating on Amylyx Pharmaceuticals Inc (AMLX) with a price target of $30.00. Fernandez, who focuses on the Healthcare sector, has an average return of 25.0% and a 61.33% success rate on his stock recommendations. Additionally, LifeSci Capital also assigned a Buy rating to AMLX with a price target of $24.00 in a report released on May 9."
datetime: "2026-05-11T11:40:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285935233.md)
  - [en](https://longbridge.com/en/news/285935233.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285935233.md)
---

# Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Guggenheim

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $30.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Fernandez covers the Healthcare sector, focusing on stocks such as MBX Biosciences, Inc., Rhythm Pharmaceuticals, and Bristol-Myers Squibb. According to TipRanks, Fernandez has an average return of 25.0% and a 61.33% success rate on recommended stocks.

In a report released on May 9, LifeSci Capital also assigned a Buy rating to the stock with a $24.00 price target.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [RYTM.US](https://longbridge.com/en/quote/RYTM.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus](https://longbridge.com/en/news/286360144.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/286678740.md)
- [Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/286913304.md)